Semaglutide Fass: reading the Swedish data sheet as a UK patient

Step 1: understand what Fass is, and what it is not for UK patients

Fass.se is run by the Swedish pharmaceutical trade association LIF. It publishes summaries of product characteristics and patient information leaflets for medicines marketed in Sweden, all regulated under the European Medicines Agency framework. When semaglutide appears on Fass, the document covers the EMA-authorised version of the product. Sweden and the UK now operate separate regulatory regimes: since Brexit, the MHRA has been the licensing authority for medicines sold in Great Britain, and its approved product information can differ from the EMA version in ways that matter clinically.

For a UK patient, reading a Fass entry can feel like reading a foreign-language instruction manual for a broadly similar but not identical product. The molecule is the same. The mechanism is the same. The side-effect profile is broadly the same. But brand names, approved doses, the packaging format you would receive, and the prescribing guidance your clinician follows all come from MHRA authorisations and NHS guidance, not from Sweden's database. That distinction is not a technicality, it affects what your prescriber can legally supply and what you should expect in practice. If you want detailed product information for the UK, the right document is the semaglutide SmPC on the electronic Medicines Compendium, which publishes MHRA-authorised UK product information.

A quick note on language: some patients arrive at Fass because they originally researched semaglutide in Swedish or because a Swedish forum recommended it. If that describes your situation, the good news is that the clinical evidence behind semaglutide is the same wherever you live; only the access route differs. The semaglutide overview on this site walks through what that means in a UK context.

Step 2: semaglutide's two licensed UK products for weight management

In the UK, semaglutide for weight management comes in two MHRA-approved forms. The first is Wegovy, the once-weekly subcutaneous injection made by Novo Nordisk. Treatment begins at 0.25 mg and moves through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, with roughly four weeks at each step. In January 2026 the MHRA approved a higher 7.2 mg maintenance dose, and on 14 April 2026 the regulator approved a dedicated single-dose 7.2 mg pen (one pre-set injection per week) for adults with a BMI of 30 or above. The STEP 1 trial, published in the New England Journal of Medicine, recorded an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg dose.

The second form is the Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight loss in the UK. The maintenance dose is 25 mg once daily, reached gradually from 1.5 mg. It is taken first thing in the morning with a small amount of plain water, at least 30 minutes before any food or other medicines. Because it does not require refrigeration, many people find it easier to travel with than an injection pen. In the OASIS 4 trial, participants who stayed fully adherent achieved around 17% average weight loss over 64 weeks, though the overall trial average, regardless of adherence, was approximately 13.6%. Read more about the Wegovy product context if you want to compare the two formats directly.

Ozempic is also semaglutide, also made by Novo Nordisk, but it carries a UK licence only for type 2 diabetes. It is not licensed or prescribed here for weight management, and it should not be conflated with Wegovy. That distinction sometimes surprises people, because the molecules are identical; the difference lies entirely in the licence and the dose.

Step 3: who the UK licence covers and what the prescription process involves

The MHRA licence for Wegovy injection covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 where at least one weight-related condition is present, for example high blood pressure, raised cholesterol, obstructive sleep apnoea or type 2 diabetes. The Wegovy tablet carries the same broad eligibility. NICE has separately recommended semaglutide injection (TA875) within specialist NHS weight management services for a maximum of two years, with additional criteria around comorbidities and BMI thresholds.

A BMI figure alone never decides suitability. Every prescription requires a clinical assessment by a qualified prescriber who reviews your health history, any current medicines and potential contraindications. Semaglutide is not recommended in pregnancy, during breastfeeding or for people trying to conceive, and it is not licensed for anyone under 18. If you take oral contraceptives, it is worth raising that with your prescriber; NHS guidance specifically addresses the interaction between GLP-1 medicines and pill absorption. For a fuller picture of eligibility, the weight-loss treatment overview sets out how that clinical picture is built.

On the NHS, access to Wegovy is through specialist services and waiting lists are often long. NICE criteria for NHS tirzepatide (the alternative dual-agonist) are also phased. Many people choose a regulated private pharmacy as an alternative, provided the same clinical safeguards apply. That is a reasonable question to take to a consultation rather than to decide from a medicines data sheet.

Step 4: side effects, safety signals and the right information sources

The side-effect profile that appears on a Fass data sheet for semaglutide is broadly consistent with UK sources, because the underlying clinical evidence is the same. Gastrointestinal effects (nausea, loose stools, constipation, reflux, tiredness) are most common, particularly when starting or moving to a higher dose, and tend to settle within one to two weeks for most people. Injection-site reactions occur for some users, and if you are curious about how the medicine is typically supplied you can find out more about what a bottle of semaglutide looks like and contains.

Two safety points are worth calling out explicitly. In January 2026, the MHRA issued a Drug Safety Update flagging acute pancreatitis as an infrequent but potentially serious effect of GLP-1 medicines. Severe stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. Second, if you have surgery planned, your prescriber and anaesthetist need to know you are taking semaglutide; some patients also ask about combining semaglutide with other compounds, and our page on BPC-157 and semaglutide covers what is currently understood about that combination. Both safety points are covered in detail on the NHS semaglutide page.

Patients and healthcare professionals can report suspected side effects to the MHRA through the Yellow Card scheme. That scheme also accepts reports of suspect sellers, a relevant point given the volume of counterfeit weight-loss medicines circulating online. A legitimate supply always comes via a prescription from a registered pharmacy; anything offered without a clinical assessment is a red flag, whatever the data sheet says about the molecule.

If you are considering whether semaglutide is appropriate for you, a consultation with a qualified prescriber is the right starting point. At nume, a GPhC-registered prescriber (a real clinician, not an algorithm) reads your consultation the same day. If approved, treatment is dispatched the same day before 12pm and arrives the next working day via DPD, in plain unbranded packaging with no indication of the contents. You can verify our pharmacy on the GPhC register at registration number 9012878. Patients who want a closer look at dosing before they begin may find our guide to the semaglutide 1 mg dose a useful reference point. To take the first step, start your free consultation.